Marshall Wace’s Mural Oncology MURA Stock Holding History

Marshall Wace’s Portfolio MURA Stock Details MURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-42,324	Closed	-$207K	–	2806
2024 Q1	$207K	Sell	42,324 -32,715	-44%	-$159K	﹤0.01%	2224
2023 Q4	$444K	Buy	+75,039	New	+$302K	﹤0.01%	1756

Other funds holding MURA

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace's MURA Position: Q2 2024 in Review

Marshall Wace sold out of Mural Oncology (MURA) in Q2 2024, closing a stake of 42,324 shares — an estimated $207K sold.

Marshall Wace first reported a position in MURA in Q4 2023 and held it in 2 quarters. The position peaked at $444K in Q4 2023. 86 funds tracked by Wall St. Rank hold MURA as of Q2 2024.

Marshall Wace reported no remaining Mural Oncology position as of Q2 2024 after selling out during the quarter.
Marshall Wace sold 42,324 Mural Oncology shares in Q2 2024, an estimated $207K.
Marshall Wace first reported a position in Mural Oncology in Q4 2023 and held it in 2 quarters.
Marshall Wace's Mural Oncology position peaked at $444K in Q4 2023.
86 funds tracked by Wall St. Rank held Mural Oncology as of Q2 2024.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.